Critical Limb Ischemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Critical Limb Ischemia – Drugs In Development, 2024 report and make more profitable business decisions.
Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet, and hands. Symptoms include pain or numbness in feet or toes, sores, and skin infections that do not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life, and increasing survival.
The Critical Limb Ischemia drugs in development market research report provide comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Critical Limb Ischemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 34 molecules, with 32 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Critical Limb Ischemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Critical Limb Ischemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Critical Limb Ischemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Ambulero IncAntidote Therapeutics Inc
Aplagon Oy
Athersys Inc
Constant Therapeutics LLC
Cynata Therapeutics Ltd
Elphis Cell Therapeutics Co Ltd
Gurus BioPharm Inc
Helixmith Co Ltd
Hemostemix Inc
ID Pharma Co Ltd
ImmuneCyte Inc
Kangstem Biotech Co Ltd
Libella Gene Therapeutics
Lisata Therapeutics Inc
MabTics
Nihon University School of Medicine
Orgenesis Inc
Pharmicell Co Ltd
Pluri Inc
ReeLabs Pvt Ltd
Reven Holdings Inc
S.Biomedics Co Ltd
Taiwan Bio Therapeutics Co Ltd
Theratome Bio Inc
University of California Davis
VESSL Therapeutics Ltd
Vivazome Therapeutics Pty Ltd
Yichang Humanwell Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Critical Limb Ischemia reports